AbbVie reported that its dual-acting multiple myeloma bispecific, etentamig, met the main goal in a Phase 3 trial, improving progression-free outcomes versus standard regimens in patients who had progressed on two or more prior therapies. The company said etentamig cut the risk of disease progression or death by 60% compared with control and highlighted low rates of serious immune responses that have been associated with other bispecific drugs. In the trial, AbbVie enrolled 421 participants and randomized them to etentamig or standard treatment, with investigators unblinded after independent monitors identified differences at a pre-planned interim checkpoint. The mechanism centers on a T-cell engager approach: the bispecific antibody binds tumor cells and recruits T cells to drive an anti-myeloma immune response. Strategically, the readout lands as the category increasingly competes on both efficacy durability and tolerability, particularly around cytokine release syndrome and related neurological toxicity. If etentamig’s safety profile translates in broader practice settings, AbbVie positioned it as potentially enabling greater use in community oncology centers with less intensive post-treatment monitoring.